Results 21 to 30 of about 205,861 (285)

Clinical manifestations and outcomes of pediatric chronic neutropenia

Journal of the Formosan Medical Association, 2012
Neutropenia is a decrease in the number of circulating neutrophils. When neutropenia persists for more than 3 months, it becomes chronic. A heterogeneous group of diseases in children can cause chronic neutropenia.
Chuan Wan, Hsin-Hui Yu, Meng-Yao Lu, Jyh-Hong Lee, Li-Chieh Wang, Yu-Tsan Lin, Yao-Hsu Yang, Bor-Luen Chiang   +7 more
doaj   +1 more source

Association between radioactive iodine uptake and neutropenia in untreated Graves’ disease

Endocrine Connections, 2023
Objective: Neutropenia is a complication of Graves' disease (GD), but there is currently no means by which to predict its occurrence. This study aimed to investigate the risk factors for the development of neutropenia in untreated GD. Methods: This was
Qian Yang, Wencai Ke, Fanfan Pan, Xinmei Huang, Jun Liu, Bingbing Zha   +5 more
doaj   +1 more source

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study [PDF]

, 2018
Purpose: Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and 6, has demonstrated preclinical activity in non–small cell lung cancer (NSCLC).
Beckmann, Richard, Garrido, Pilar, Goldman, Jonathan W., Gutierrez, Martin, Hossain, Anwar, Jalal, Shadia, John, William J., Johnston, Erica L., Kambhampati, Siva Rama Prasad, Kelly, Karen, Kim, Edward S., Mahadevan, Daruka, Paz-Ares, Luis G., Provencio, Mariano, Schaefer, Eric, Shaheen, Monte, Turner, P. Kellie   +16 more
core   +2 more sources

Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs. [PDF]

, 2015
BackgroundNonresectable mast cell tumors (MCT) in dogs remain a therapeutic challenge, and investigation of novel combination therapies is warranted. Intermittent administration of tyrosine kinase inhibitors (TKI) combined with cytotoxic chemotherapy may
Avery, AC, Axiak-Bechtel, SM, Burton, JH, Clifford, CA, Thamm, DH, Vail, DM, Venable, RO, Williams, LE   +7 more
core   +1 more source

Costs associated with febrile neutropenia in solid tumor and lymphoma patients - an observational study in Singapore. [PDF]

, 2014
BackgroundThe primary objective was to describe the total direct inpatient costs among solid tumor and lymphoma patients with chemotherapy-induced febrile neutropenia (FN) and the factors that were associated with higher direct cost.
A Bosly, A Chan, A Ihbe-Heffinger, AG Freifeld, Alexandre Chan, B Dulisse, C O’Brien, CL Bennett, GH Lyman, GH Lyman, GH Lyman, H Khalili, J Klastersky, JI Mayordomo, Li Yang Hsu, LM Poon, M Wong, Mabel Wong, MB Schilling, NM Kuderer, SL Michels, SY Liou, V Caggiano, Xiao Jun Wang, YP Zhou   +24 more
core   +2 more sources

Metronomic chemotherapy preserves quality of life ensuring efficacy in elderly advanced non small cell lung cancer patients [PDF]

, 2016
Metastatic non small cell lung cancers (NSCLC) are diseases with poor prognosis and platinum-based doublet chemotherapy still remains their standard cure.
DE IULIIS, Francesca, Lanza, Rosina, Salerno, Gerardo, Scarpa, Susanna, Taglieri, Ludovica, Vendittozzi, Stefania   +5 more
core   +1 more source

Clinical spectrum of pediatric neutropenia: mostly benign, but not to be overlooked

The Turkish Journal of Pediatrics
Background. Neutropenia is a common laboratory finding in children, therefore it is a common referral reason to pediatric hematology units. This study hypothesizes that most neutropenic children do not require pediatric hematology consultation, and that
Şefika Akyol, Özlem Tüfekçi, Şebnem Yılmaz, Hale Ören   +3 more
doaj   +1 more source

Predictive value of hematological and phenotypical parameters on postchemotherapy leukocyte recovery [PDF]

, 2009
Background: Grade IV chemotherapy toxicity is defined as absolute neutrophil count <500/μL. The nadir is considered as the lowest neutrophil number following chemotherapy, and generally is not expected before the 7th day from the start of chemotherapy.
Abbasciano V, Albertini F, Barile C, Bononi A, CAMPIONI, Diana, Crepaldi G, Ferrari L, Ferrazzi E, Gilli G, Gusella M, Lanza F, Menon D, Pasini F., Russo A, Stievano L, Toso S   +15 more
core   +1 more source

Efficacy and Safety of In-Asia-Manufactured rhG-CSF 300 mcg As Primary Prophylaxis for Prevention of CHOP Chemotherapy-induced Severe Neutropenia in Elderly Patients with Lymphoma Non-Hodgkin

Indonesian Journal of Cancer, 2009
We conducted open label, non-comparative trial in patients aged > 60 with advanced and intermediate-grade NonHodgkin Lymphoma (NHL) (stadium II, III, IV) to evaluate the efficacy and safety of In-Asia-manufactured rhG-CSF 300 mcg for prevention of CHOP (
Harryanto Reksodiputro, Zubairi Djoerban, Karmel L. Tambunan, Aru W. Sudoyo, Abidin Widjanarko, Djumhana Atmakusuma, Syafrizal Syafei, Nugroho Prayogo, Ronald Hukom, Dody Ranuhardy, Zakifman Jack, Asrul Harsal, Noorwati S, Bambang Karsono, Shufrie Effendi, Hilman Tadjoedin   +15 more
doaj   +1 more source

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations. [PDF]

, 2017
Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel.
Hoffman-Censits, Jean, Patel, Sheel
core   +3 more sources